GNI Group

2160.TSE

20.52 USD

-1.57

-7.11%

Overview

Last close

20.52 usd

Market cap

1.03B usd

52 week high

25.28 usd

52 week low

8.42 usd

Target price

24.61 usd

Valuation

P/E

22.4039

Forward P/E

N/A

Price/Sales

6.8082

Price/Book Value

4.3707

Enterprise Value

931.96M usd

EV/Revenue

6.4343

EV/EBITDA

14.072

Key financials

Revenue TTM

151.19M usd

Gross Profit TTM

94.27M usd

EBITDA TTM

9.87M usd

Earnings per Share

0.88 usd

Dividend

N/A usd

Total assets

429.09M usd

Net debt

-63.97M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.